Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
New data add to the body of evidence supporting efficacy of omidubicel, Gamida Cell's lead product candidate, which has a target PDUFA action date with U.S. Food and Drug Administration (FDA) of May 1, 2023 New data for GDA-201, Gamida Cell's …